Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5735)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2015 (publication date) through May 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ge GH, Ye Y, Zhou XB, Chen L, He C, Wen DF, Tan YW. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients. World J Gastroenterol 2015; 21(28): 8653-8659 [PMID: 26229407 DOI: 10.3748/wjg.v21.i28.8653] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i28/8653.htm |
| Number | Citing Articles |
| 1 |
Issam Tout, Pietro Lampertico, Thomas Berg, Tarik Asselah. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Research 2021; 185: 104992 doi: 10.1016/j.antiviral.2020.104992
|
| 2 |
Mengqi Luo, Bin Zhou, Jinlin Hou, Deke Jiang. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatology Research 2022; 52(4): 337 doi: 10.1111/hepr.13749
|
| 3 |
Yun Liu, Minglei Jia, Shengdi Wu, Wei Jiang, Yifan Feng. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis. International Journal of Infectious Diseases 2019; 86: 201 doi: 10.1016/j.ijid.2019.07.036
|
| 4 |
Chern Hao Chong, Seng Gee Lim. When can we stop nucleoside analogues in patients with chronic hepatitis B?. Liver International 2017; 37(S1): 52 doi: 10.1111/liv.13314
|
| 5 |
Grishma Hirode, Hannah S.J. Choi, Chien-Hung Chen, Tung-Hung Su, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sabela Lens, Grace Wong, Sylvia M. Brakenhoff, Rong-Nan Chien, Jordan Feld, Milan J. Sonneveld, Henry L.Y. Chan, Xavier Forns, George V. Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Yao-Chun Hsu, Jia-Horng Kao, Markus Cornberg, Bettina E. Hansen, Wen-Juei Jeng, Harry L.A. Janssen. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology 2022; 162(3): 757 doi: 10.1053/j.gastro.2021.11.002
|
| 6 |
Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson. The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020; 12(9): 934 doi: 10.3390/v12090934
|
| 7 |
Yin Wu, Jiaojiao Fan, Guichan Liao, Muye Xia, Deke Jiang, Jie Peng, Xiaoyong Zhang, Hongyan Liu. Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B. Infection, Genetics and Evolution 2020; 78: 104124 doi: 10.1016/j.meegid.2019.104124
|